Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir

Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study

The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.

Inclusion Criteria:

• liver transplantation for hepatitis B induced endstage liver disease
• absence of coinfection with HIV and HCV
• female and male patients >= 18 years of age

Exclusion Criteria:

• any evidence of other causes for endstage liver disease
• patients that do not fulfill the criteria for liver transplantation